lilly direct tirzepatide vial Eli announces it's releasing new form of Zepbound Lilly's tirzepatide reduces type 2

I worry that in dealing with people with cravings, and people at risk of overdosing and other problems, that we need to understand and appreciate the uncertainties here more. He says that another issue that must be explored further before prescribing GLP-1s to prevent or treat addictions is the ability of the brain to adapt

Duttaroy, A., et al

Accurately identifying and subgrouping autoantibodies in patients plays a huge role in the subsequent tailoring of therapeutic strategies and prognosis according to the characteristics of different antibodies

IL-1 cytokines trigger symptoms associated with gastrointestinal diseases, including pain, vasodilation and hypotension, fever and several autonomic adaptations during inflammation such as tachycardia, changes in metabolism and behaviour

Announced by Novo Nordisk on May 2, 2025, the investigational oral formulation of semaglutide is targeted for chronic weight management in patients with obesity or overweight and 1 comorbid condition and to reduce the risk of major adverse cardiovascular events (MACE) in those with overweight or obesity and established cardiovascular disease

One trial had a 12week duration [23], one had a 26week duration [13, 25], one had a 28week duration [24], four had 40week durations [31, 32, 35, 37], seven had 52week durations [29, 30, 33, 34, 36, 38, 39], and the other three spanned 72 weeks [26, 27, 28]